Novel genetic biomarkers for susceptibility to oral submucous fibrosis: Cytochrome P450 3A

Medical Hypotheses

Volumn 77, Issue 5, 2011, Pages 834-836

  Li, Ning ^a   Hu, Qiong ^b   Jiang, Canhua ^a   Hu, Yanjia ^a   Yuan, Yongxiang ^a   Jian, Xinchun ^a   Tang, Zhangui ^a   Guo, Feng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b The Second People's Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; BETEL EXTRACT; CYTOCHROME P450 3A; MESSENGER RNA; VINCRISTINE; XENOBIOTIC AGENT;

AEROBIC METABOLISM; ALLELE; ARTICLE; BETEL NUT; BREAST CANCER; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MOUTH DISEASE; PERIPHERAL NEUROPATHY;

CYTOCHROME P-450 CYP3A; GENETIC MARKERS; HUMANS; MOUTH MUCOSA;

PIPER BETEL;

EID: 80053960225     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.07.049     Document Type: Article

References (13)

1. Murti P.R., Bhonsie R.B., Pindborg J.J., Daftary D.K., Gupta P.C., Mehta F.S. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol 1985, 13:340-341.
2. Pindorg J.J. Oral submucous fibrosis: a review. Ann Acad Med Singapore 1989, 18:603-607.
3. Reichart P.A., Philipsen H.P. Betel and Miang: vanishing Thai habits 2005, White Lotus Ltd. Co., Bangkok. 2nd ed.
4. Kakuda T.N., Schöller-Gyüre M., Hoetelmans R.M. Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir Ther 2010, 15(6):817-829.
5. Lin J.H. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 2006, 23:1089-1116.
6. Li Ning, Jian Xinchun, Hu Yanjia, Xu Chunjiao, Gang Yaozhi, Zhong Xiaohuan Discovery of novel biomarkers in oral submucous fibrosis by microarray analysis. Cancer Epidemiol Biomarkers Prev 2008, 17(9):2249-2259.
7. Lamba J.K., Lin Y.S., Thummel K., et al. Common allelic variants of cytochrome P450 3A4 and their prevalence in different populations. Pharmacogenetics 2002, 12:121-132.
8. Schöller-Gyüre M., Kakuda T.N., Raoof A., De S.G., Hoetelmans R.M. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 2009, 48(9):561-749.
9. Paulussen A., Lavrijsen K., Bohets H., et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 2000, 10:415-424.
10. Wang H., Dick R., Yin H., et al. Structure-function relationships of human liver cytochrome P450 3A: Aflatoxin B1 metabolism as a probe. Biochemistry (Mosc) 1998, 37:12536-12545.
11. Lin Y.S., Dowling A.L., Quigley S.D., et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002, 62:162-172.
12. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27:383-391.
13. Cali J.J., Ma D., Sobol M., Simpson D.J., Frackman S., Good T.D., et al. Luminogenic cytochrome P450 assays. Expert Opin Drug Metab Toxicol 2006, 2(4):629-645.